SCHEMBL1380787

SCHEMBL1380787

COc1ccc(OC)c(NC(=O)c2cc(C)n(-c3ccccc3C(F)(F)F)c2C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 5/20 0.49
MAPT P10636 5/20 0.49
NPSR1 Q6W5P4 4/20 0.49
KDM4E B2RXH2 3/20 0.49
ATM Q13315 2/20 0.49
HPGD P15428 2/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
GAA P10253 3/20 0.48
TP53 P04637 1/20 0.46
RBP4 P02753 1/20 0.46
NR1I2 O75469 1/20 0.45
CREBBP Q92793 1/20 0.45
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PPARG P37231 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1382774 0.92 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2LMNAMAPTKDM4E
SCHEMBL1381266 0.91 EPHX2 (0.43) ALDH1A1SMN1; SMN2LMNAMAPTNPSR1
SCHEMBL1383979 0.91 HSD17B10 (0.47) ALDH1A1SMN1; SMN2MAPTNPSR1KDM4E
SCHEMBL1379991 0.90 KDM4E (0.48) ALDH1A1SMN1; SMN2MAPTKDM4EHPGD
SCHEMBL1380796 0.90 RAB9A (0.47) ALDH1A1SMN1; SMN2LMNAMAPTKDM4E
SCHEMBL1378563 0.90 KMT2A (0.50) SMN1; SMN2LMNAMAPTTSHRHSD17B10
SCHEMBL1379707 0.89 CYP1A2 (0.47) LMNAMAPTNPSR1TSHRMEN1
SCHEMBL1381902 0.89 RBP4 (0.59) ALDH1A1SMN1; SMN2KDM4EHPGDMEN1
SCHEMBL1382233 0.89 KMT2A (0.53) ALDH1A1LMNAMAPTKDM4EHPGD
SCHEMBL1382701 0.89 NR1H4 (0.47) ALDH1A1MAPTKDM4EHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4703649-B2 2011-06-15 JP claimed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-20110144128-A1 Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands EXELIXIS, INC. (US) 2011-06-16 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 ALDH1A1 2251/4885SMN1; SMN2 3536/4885LMNA 4213/4885
US-20110144128-A1 Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands NCOA1, NCOA2, NCOA3 ALDH1A1 1665/4885SMN1; SMN2 4731/4885LMNA 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.